New combo targets tough colorectal cancer in Liver-Free patients
NCT ID NCT06856837
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase II trial tests whether combining fruquintinib (a targeted therapy) with tislelizumab (an immunotherapy) can help people with a specific type of advanced colorectal cancer that has not spread to the liver. The study will enroll 140 participants whose tumors are microsatellite stable (MSS), a form that typically does not respond well to immunotherapy alone. The main goal is to see if the combination delays cancer growth compared to standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fruquintinib and tislelizumab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with a hard-to-treat type of colorectal cancer that has spread but not to the liver.
- What could go wrong
- This is an early Phase II trial with only 140 people, so results are not definitive. The combination may not improve survival and could cause side effects like immune-related reactions or high blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asklepios Kliniken Hamburg GmbH
NOT_YET_RECRUITINGHamburg, Germany
-
Charite Universitaetsmedizin Berlin KöR
RECRUITINGBerlin, Germany
-
Goethe University Frankfurt
RECRUITINGFrankfurt, Germany
-
HELIOS Emil von Behring Berlin
RECRUITINGBerlin, Germany
-
HELIOS Klinikum Bad Saarow
RECRUITINGBad Saarow, Germany
-
Hamburg Hämatologisch-Onkologische Praxis Eppendorf-Facharztzentrum Eppendorf
RECRUITINGHamburg, 20246, Germany
-
Institut für Klinisch-Onkologische Forschung am Krankenhaus Nordwest
RECRUITINGFrankfurt am Main, 60488, Germany
-
KEM | Klinik für Internistische Onkologie gGmbH
RECRUITINGEssen, 45136, Germany
-
Katholisches Klinikum Bochum gGmbH
NOT_YET_RECRUITINGBochum, Germany
-
Klinikum Mutterhaus der Borromäerinnen gGmbH
NOT_YET_RECRUITINGTrier, Germany
-
Klinikum St. Marien Amberg
RECRUITINGAmberg, Germany
-
Klinikum der Universität München AöR
RECRUITINGMünchen, Germany
-
Klinikum rechts der Isar TU München
RECRUITINGMünchen, Germany
-
Leopoldina Krankenhaus Schweinfurt
RECRUITINGSchweinfurt, Germany
-
Marienhospital Herne
RECRUITINGHerne, Germany
-
Noe LGA Gesundheit Thermenregion GmbH
NOT_YET_RECRUITINGWiener Neustadt, Austria
-
Ordensklinikum Linz GmbH
NOT_YET_RECRUITINGLinz, Austria
-
SCRI CCCIT Ges.m.b.H.
RECRUITINGSalzburg, Austria
-
University Medical Center Hamburg-Eppendorf
RECRUITINGHamburg, Germany
-
Universitätsklinikum Düsseldorf Klinik für Gastroenterologie, Hepatologie und Infektiologie Gastroonkologische Studienzentrale
NOT_YET_RECRUITINGDüsseldorf, 40225, Germany
-
Universitätsklinikum Essen
NOT_YET_RECRUITINGEssen, 45147, Germany
-
Universitätsklinikum Ulm
RECRUITINGUlm, 89081, Germany
-
Vincentius-Diakonissen-Kliniken gAG
NOT_YET_RECRUITINGKarlsruhe, 76137, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?